Tagged with P

China Since raising USD 289 million in its Spring 2020 Hong Kong IPO, InnoCare Pharma has had a remarkable rise. Led by a team of Big Pharma veterans and now also listed in Shanghai, the firm has secured regulatory approvals for its BTK inhibitor for haematological cancers in mainland China and…

China Eye health, despite being essential for most of us in our daily lives, receives significantly less research funding than fields like cancer or diabetes. According to IQVIA, global spending on oncology is expected to reach USD 440 billion by 2028, while ophthalmology will see just USD 38 billion. However, conditions…

China There are over 7,000 different rare diseases globally, many of which affect only a handful of patients. However, given the scale of China’s population, rare diseases in the country take on an increased significance, something that Chinese policymakers have worked to address in recent years.   “China now introduces new…

China While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life sciences ecosystem. Eased restrictions on foreign investment have made it even more attractive for international pharma while China’s native innovators…

China Beyond political, cultural, economic, and linguistic concerns, the sheer pace of Chinese pharma’s development makes it challenging for international observers to fully grasp the sector’s intricacies, challenges, and numerous opportunities. Thankfully, in order to untangle this complex web PharmaBoardroom spoke directly to the heads of PhIRDA – the association representing…

Europe Jazz Pharmaceuticals is about to open a new chapter in its history. As long-standing CEO and co-founder Bruce Cozadd prepares to step down for retirement, the neuroscience and oncology-focused company begins its search for a new leader and gets ready to commercialize recently FDA-approved HER2-targeted bispecific antibody, Ziihera.    End…

China 2024 marks 30 years for Takeda in China, and the company has been outstripping the overall market to grow by double-digits in the country since 2020. Sean Shan discusses how he has led this remarkable trajectory, focusing on Takeda’s strategic vision, key product launches, and commitment to innovation. He highlights…

LatAm A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4 million investment in Brazil, and SteinCares’ plasma derivatives deal with Biotest.   Record dengue outbreak in Americas kills 7,700 this…

Saudi Arabia If the number of strategic deals and industry announcements coming out of the recent CPHI Middle East in Riyadh are anything to go by, Saudi Arabia’s ambition to become a regional and global innovation hub is becoming a reality. Read on for some highlights from the first regional edition of…

India Shagun Sharma, Vipul Kumar Gupta, and Helene Sou of Takeda, writing in the December 2024 edition of DIA’s Global Forum magazine, look at how updates to India’s regulatory framework for pharmaceuticals are impacting the industry.   Since 2001, the regulatory environment for clinical research and drug development in India has…

Africa John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into Africa have yet to reach fruition.   Recent pandemics have triggered calls for deglobalization in the production of medical products…

Puerto Rico CytoImmune, founded in 2017 and established in Puerto Rico in 2020, is focused on developing immune-based therapies using proprietary natural killer (NK) cells. CEO Dr José Eduardo Vidal discusses the biotech’s innovative approach, the access promise of allogeneic NK cells as opposed to T-cell therapies, the advantages of setting up…